| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S19458 R82954 |
Straub (Controls exposed to LTG) (Levetiracetam) (Epilepsy), 2026 | Attention deficit hyperactivity disorder (ADHD) - ICD-10 codes: F90.x - Mean follow up (full cohort): 3.4 years | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
0.56 [0.41;0.76] C excluded (control group) |
69/3,929 102/3,273 | 171 | 3,929 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S19468 R83042 |
Straub (Controls unexposed, sick) (Levetiracetam) (Epilepsy), 2026 | Attention deficit hyperactivity disorder (ADHD) - ICD-10 codes: F90.x - Mean follow up (full cohort): 3.4 years | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes | 0.89 [0.68;1.17] | 69/3,929 366/8,887 | 435 | 3,929 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17431 R73237 |
Madley-Dowd_SE (Levetiracetam) (Controls exposed to LTG), 2024 | Attention Deficit Hyperactivity Disorder - ICD-8/9/10 codes and/or ADHD medication prescription - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No Partial overlapping |
0.54 [0.31;0.95] C excluded (control group) |
14/556 109/2,383 | 123 | 556 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17432 R73238 |
Madley-Dowd_SE (Levetiracetam) (Controls unexposed, sick), 2024 | Attention Deficit Hyperactivity Disorder - ICD-8/9/10 codes and/or ADHD medication prescription - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes Partial overlapping | 0.99 [0.58;1.68] | 190/556 929/10,769 | 1,119 | 556 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17252 R72261 |
Madley-Dowd_UK (Levetiracetam) (Epilepsy), 2024 | Attention Deficit Hyperactivity Disorder - ICD10 codes and/or ADHD medication prescription - Median 4.19 (2.56-6.79) years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes | 1.23 [0.16;9.58] | -/174 38/4,075 | - | 174 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15871 R65402 |
Dreier (Levetiracetam) (Epilepsy) (Controls exposed to LTG), 2023 | Attention-deficit/hyperactivity disorder (ADHD) - Corresponding ICD-10 F-chapter - Up to 22 years of age | during pregnancy (anytime or not specified) | population based cohort propective | exposed to other treatment, sick excluded | Adjustment: No |
0.73 [0.42;1.29] C excluded (control group) |
14/1,061 95/5,288 | 109 | 1,061 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15872 R65410 |
Dreier (Levetiracetam) (Epilepsy) (Controls unexposed, sick), 2023 | Attention-deficit/hyperactivity disorder (ADHD) - Corresponding ICD-10 F-chapter - Up to 22 years of age | during pregnancy (anytime or not specified) | population based cohort propective | unexposed, sick | Adjustment: Yes | 1.78 [1.03;3.07] | 14/1,061 528/22,203 | 542 | 1,061 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7511 R46410 |
Huber-Mollema (Levetiracetam), 2019 | Diagnosis of ADHD | throughout pregnancy | prospective cohort | exposed to other treatment, sick | Adjustment: No | 0.25 [0.01;4.74] C | 0/30 5/88 | 5 | 30 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7308 R46411 |
Bromley (Levetiracetam), 2016 | Maladaptive behavior: Attention (BASC) (5-9 years old) | during pregnancy (anytime or not specified) | retrospective cohort (registry) | unexposed, sick | Adjustment: No extrapolated (cont. endpoint) | 0.86 [0.41;1.78] | -/42 -/55 | - | 42 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 6 studies | 1.03 [0.79;1.34] | 2,101 | 5,792 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, sick) (Levetiracetam) (Epilepsy; 2: Levetiracetam) (Controls unexposed, sick; 3: Levetiracetam) (Epilepsy; 4: Levetiracetam) (Epilepsy) (Controls unexposed, sick; 5: Levetiracetam; 6: Levetiracetam;
Asymetry test p-value = 0.9426 (by Egger's regression)
slope=-0.0178 (0.2309); intercept=0.0674 (0.8800); t=0.0766; p=0.9426
excluded 15871, 17431, 19458